pmc logo image
New dosing schedules of dasatinib for CML and adverse event management
Siu-Fun Wong
J Hematol Oncol. 2009; 2: 10. Published online 2009 February 23. doi: 10.1186/1756-8722-2-10
PMCID:
PMC2649947
Abstract Full Text PDF–309K Supplementary Material
 Is Cited by the Following 2 Articles in this Archive:
Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
Mariana Serpa, Sabri S. Sanabani, Israel Bendit, Fernanda Seguro, Flávia Xavier, Cláudia Bitti Barroso, Monika Conchon, Pedro Enrique Dorlhiac-Llacer
Clin Med Insights Oncol. 2010; 4: 155–162. Published online 2010 December 19. doi: 10.4137/CMO.S6413
PMCID:
PMC3018898
Abstract Full Text PDF–485K
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Guoqing Wei, Shamudheen Rafiyath, Delong Liu
J Hematol Oncol. 2010; 3: 47. Published online 2010 November 26. doi: 10.1186/1756-8722-3-47
PMCID:
PMC3000369
Abstract Full Text PDF–291K
You are here: NCBI > Literature > PubMed Central
Write to the Help Desk